financetom
Business
financetom
/
Business
/
HPQ Silicon Details "Latest Significant Battery Milestones" Achieved by France-based affiliate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HPQ Silicon Details "Latest Significant Battery Milestones" Achieved by France-based affiliate
Aug 21, 2024 10:24 AM

07:54 AM EDT, 08/21/2024 (MT Newswires) -- HPQ Silicon ( HPQFF ) , a technology company specializing in green engineering of silica and silicon-based materials, announced Wednesday the "latest significant battery milestones" achieved by its France-based affiliate, NOVACIUM SAS.

A statement noted this announcement covers the results of 50 charge-discharge cycle tests conducted to simulate real-world usage and assess the durability and longevity of the latest batch of Lithium-ion 18650 commercial batteries, made with a blend of graphite and Novacium's partially optimized GEN3 advanced silicon-based anode material.

HPQ said the 18650 GEN3-based batteries performed "remarkably well", with an overall capacity improvement of about 40% compared to a graphite benchmark. It added this performance is 25% higher than that of the previous GEN1 material and 15% higher than that of the GEN2 material, with performance degradation so minimal compared to the graphite benchmark that it falls within the margin of error.

"Producing 18650 battery cells that excel in charge-discharge cycle testing and exceed 4,000 mAh under maximum discharge conditions....further confirms our position as a top-tier producer of advanced silicon anode material," said Dr. Jed Kraiem, COO of Novacium. "Based on these results and the data we've gathered, we are confident that we can continue improving our material, and that GEN4-based 18650 batteries could exceed the 4,400 mAh mark."

HPQ edged up $0.005 to $0.345 on Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Liberty Media Prices $825.4 Million Public Offering
Liberty Media Prices $825.4 Million Public Offering
Aug 21, 2024
09:15 AM EDT, 08/21/2024 (MT Newswires) -- Liberty Media ( LLYVB ) said Wednesday that it priced a public offering of 10.7 million shares of its series C Liberty Formula One shares at $77.50 per share for gross proceeds of around $825.4 million. The company said it granted the underwriter an option to buy up to 1.6 million FWONK additional...
Smart for Life Shares Rise Pre-Bell Amid Multiple M&A Plans
Smart for Life Shares Rise Pre-Bell Amid Multiple M&A Plans
Aug 21, 2024
09:13 AM EDT, 08/21/2024 (MT Newswires) -- Smart for Life ( SMFL ) shares were up 165% in recent Wednesday premarket activity after the company said it is in talks to acquire several firms as part of its post-restructuring efforts. Aside from its previously announced acquisition of Purely Optimal Nutrition, Smart for Life ( SMFL ) said it is in...
Ford Stock Charges Higher On EV Strategy Shift: What Investors Need To Know
Ford Stock Charges Higher On EV Strategy Shift: What Investors Need To Know
Aug 21, 2024
Ford Motor Co ( F ) shares are getting a boost Wednesday morning after the company announced plans to broaden its electrification strategy. What To Know: Ford announced that it’s taking additional actions to deliver a profitable, capital-efficient and growing electric vehicle business, including adjusting the company’s North America vehicle roadmap to offer a range of electrification options aimed at...
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Aug 21, 2024
09:08 AM EDT, 08/21/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Wednesday that it had dosed the first patient in a trial evaluating its experimental drug, (Z)-endoxifen, in combination with Eli Lilly's ( LLY ) abemaciclib as a neoadjuvant treatment for certain high-risk breast cancer patients. The study, which is part of the I-SPY network, will involve around...
Copyright 2023-2026 - www.financetom.com All Rights Reserved